These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 37526840)
1. Clinical Trials on Advanced Therapy Investigational Medicinal Products in Spain (2004-2022): Experience and Challenges for the Future. Estévez Álamo J; Timón M; Sánchez Afán de Rivera I; Iriarte Torres B; Serrano Castro MA Adv Exp Med Biol; 2023; 1430():23-39. PubMed ID: 37526840 [TBL] [Abstract][Full Text] [Related]
2. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products in Europe. Schuessler-Lenz M; Herberts C; Reischl I; Ruiz S; Celis P; Beuneu C; Kjeken R; Timón M Adv Exp Med Biol; 2023; 1430():1-21. PubMed ID: 37526839 [TBL] [Abstract][Full Text] [Related]
3. Marketing Regulatory Oversight of Advanced Therapy Medicinal Products (ATMPs) in Europe: The EMA/CAT Perspective. Salmikangas P; Schuessler-Lenz M; Ruiz S; Celis P; Reischl I; Menezes-Ferreira M; Flory E; Renner M; Ferry N Adv Exp Med Biol; 2015; 871():103-30. PubMed ID: 26374215 [TBL] [Abstract][Full Text] [Related]
4. Regulation of Clinical Trials with Advanced Therapy Medicinal Products in Germany. Renner M; Anliker B; Sanzenbacher R; Schuele S Adv Exp Med Biol; 2015; 871():87-101. PubMed ID: 26374214 [TBL] [Abstract][Full Text] [Related]
5. Regulatory Frameworks for Advanced Therapy Medicinal Products in Thailand. Boonprasirt P; Nimvorapun S; Sawangjang C; Poonpolsub S; Yoongthong W; Dunkum P Adv Exp Med Biol; 2023; 1430():221-233. PubMed ID: 37526851 [TBL] [Abstract][Full Text] [Related]
6. [Report from the Committee for Advanced Therapies (CAT). Pitfalls on the way from concept to medical treatment with advanced therapy medicinal products]. Reiss M; Büttel IC; Schneider CK Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):822-30. PubMed ID: 21698535 [TBL] [Abstract][Full Text] [Related]
8. [Chapter 2. Clinical trials of advanced therapy medicinal products: which future for the European regulation]. Mahalatchimy A; De Grove-Valdeyron N J Int Bioethique Ethique Sci; 2018 Jul; 29(2):35-51. PubMed ID: 30767446 [TBL] [Abstract][Full Text] [Related]
9. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Kočí Z; Boráň T; Krůpa P; Kubinová Š Hum Gene Ther Clin Dev; 2018 Sep; 29(3):132-147. PubMed ID: 29869533 [TBL] [Abstract][Full Text] [Related]
10. [Academic cell therapy facilities are challenged by European regulation on advanced therapy medicinal products]. Chabannon C; Sabatier F; Rial-Sebbag E; Calmels B; Veran J; Magalon G; Lemarie C; Mahalatchimy A Med Sci (Paris); 2014 May; 30(5):576-83. PubMed ID: 24939546 [TBL] [Abstract][Full Text] [Related]
11. Planning an Academic Clinical Trial. Champion KM; Jones GR Methods Mol Biol; 2015; 1317():287-313. PubMed ID: 26072413 [TBL] [Abstract][Full Text] [Related]
12. Overview of the Regulatory Oversight Implemented by the French Regulatory Authorities for the Clinical Investigation of Gene Therapy and Cell Therapy Products. Lucas-Samuel S; Ferry N; Trouvin JH Adv Exp Med Biol; 2015; 871():73-85. PubMed ID: 26374213 [TBL] [Abstract][Full Text] [Related]
13. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States. Iglesias-Lopez C; Obach M; Vallano A; Agustí A Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292 [TBL] [Abstract][Full Text] [Related]
14. Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe. Farkas AM; Mariz S; Stoyanova-Beninska V; Celis P; Vamvakas S; Larsson K; Sepodes B Front Med (Lausanne); 2017; 4():53. PubMed ID: 28560211 [TBL] [Abstract][Full Text] [Related]
15. Issues with Tissues: Trends in Tissue-Engineered Products in Clinical Trials in the European Union. Joyce K; Buljovcic Z; Rosic G; Kaszkin-Bettag M; Pandit A Tissue Eng Part B Rev; 2023 Feb; 29(1):78-88. PubMed ID: 36062927 [TBL] [Abstract][Full Text] [Related]
16. The advanced therapy classification procedure. Overview of experience gained so far. Voltz-Girolt C; Celis P; Boucaumont M; D'Apote L; Pinheiro MH; Papaluca-Amati M Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):811-5. PubMed ID: 21698533 [TBL] [Abstract][Full Text] [Related]
17. [European Marketing Authorisation: a long process. Experiences of small biotech companies with the ATMP regulation]. Buljovčić Z Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2011 Jul; 54(7):831-8. PubMed ID: 21698536 [TBL] [Abstract][Full Text] [Related]
18. Risk of discontinuation of Advanced Therapy Medicinal Products clinical trials. Hanna E; Rémuzat C; Auquier P; Toumi M J Mark Access Health Policy; 2016; 4():. PubMed ID: 27570614 [TBL] [Abstract][Full Text] [Related]
19. RNA-based drugs and regulation: Toward a necessary evolution of the definitions issued from the European union legislation. Guerriaud M; Kohli E Front Med (Lausanne); 2022; 9():1012497. PubMed ID: 36325384 [TBL] [Abstract][Full Text] [Related]
20. Hospital Exemption for Advanced Therapy Medicinal Products: Issue in Application in the European Union Member States. Ivaskiene T; Mauricas M; Ivaska J Curr Stem Cell Res Ther; 2017; 12(1):45-51. PubMed ID: 27412678 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]